These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 28363142)

  • 21. Co-delivery of siRNA and etoposide to cancer cells using an MDEA esterquat based drug delivery system.
    Popova P; Notabi MK; Code C; Arnspang EC; Andersen MØ
    Eur J Pharm Sci; 2019 Jan; 127():142-150. PubMed ID: 30409750
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug.
    Shim G; Han SE; Yu YH; Lee S; Lee HY; Kim K; Kwon IC; Park TG; Kim YB; Choi YS; Kim CW; Oh YK
    J Control Release; 2011 Oct; 155(1):60-6. PubMed ID: 20971142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficient nanocarriers of siRNA therapeutics for cancer treatment.
    Subhan MA; Torchilin VP
    Transl Res; 2019 Dec; 214():62-91. PubMed ID: 31369717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers.
    Ofek P; Fischer W; Calderón M; Haag R; Satchi-Fainaro R
    FASEB J; 2010 Sep; 24(9):3122-34. PubMed ID: 20385622
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor-targeting multifunctional nanoparticles for siRNA delivery: recent advances in cancer therapy.
    Ku SH; Kim K; Choi K; Kim SH; Kwon IC
    Adv Healthc Mater; 2014 Aug; 3(8):1182-93. PubMed ID: 24577795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.
    Barata P; Sood AK; Hong DS
    Cancer Treat Rev; 2016 Nov; 50():35-47. PubMed ID: 27612280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy.
    Miele E; Spinelli GP; Miele E; Di Fabrizio E; Ferretti E; Tomao S; Gulino A
    Int J Nanomedicine; 2012; 7():3637-57. PubMed ID: 22915840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Delivery strategies and potential targets for siRNA in major cancer types.
    Lee SJ; Kim MJ; Kwon IC; Roberts TM
    Adv Drug Deliv Rev; 2016 Sep; 104():2-15. PubMed ID: 27259398
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrated hollow mesoporous silica nanoparticles for target drug/siRNA co-delivery.
    Ma X; Zhao Y; Ng KW; Zhao Y
    Chemistry; 2013 Nov; 19(46):15593-603. PubMed ID: 24123533
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in siRNA delivery in cancer therapy.
    Singh A; Trivedi P; Jain NK
    Artif Cells Nanomed Biotechnol; 2018 Mar; 46(2):274-283. PubMed ID: 28423924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. siRNA-mediated antitumorigenesis for drug target validation and therapeutics.
    Lu PY; Xie FY; Woodle MC
    Curr Opin Mol Ther; 2003 Jun; 5(3):225-34. PubMed ID: 12870431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.
    Zhao J; Feng SS
    Nanomedicine (Lond); 2015 Jul; 10(14):2199-228. PubMed ID: 26214357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Research progress in co-delivery of gene and chemotherapy drugs with cationic liposome carrier for cancer therapy].
    Chen WG; Liu YG; Wang SB; Chen AZ
    Yao Xue Xue Bao; 2012 Aug; 47(8):986-92. PubMed ID: 23162893
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular therapy using siRNA: Recent trends and advances of multi target inhibition of cancer growth.
    Jain S; Pathak K; Vaidya A
    Int J Biol Macromol; 2018 Sep; 116():880-892. PubMed ID: 29782974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nanoparticle-mediated co-delivery of chemotherapeutic agent and siRNA for combination cancer therapy.
    Xiao B; Ma L; Merlin D
    Expert Opin Drug Deliv; 2017 Jan; 14(1):65-73. PubMed ID: 27337289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanodelivery systems for nucleic acid therapeutics in drug resistant tumors.
    Iyer AK; Duan Z; Amiji MM
    Mol Pharm; 2014 Aug; 11(8):2511-26. PubMed ID: 24661041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of RNA interference-based therapeutics and application of multi-target small interfering RNAs.
    Li T; Wu M; Zhu YY; Chen J; Chen L
    Nucleic Acid Ther; 2014 Aug; 24(4):302-12. PubMed ID: 24796432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Systemic delivery of small RNA using lipid nanoparticles.
    Asai T; Oku N
    Biol Pharm Bull; 2014; 37(2):201-5. PubMed ID: 24492716
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of new RNAi therapeutics.
    Liu G; Wong-Staal F; Li QX
    Histol Histopathol; 2007 Feb; 22(2):211-7. PubMed ID: 17149694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-coding RNAs: Therapeutic Strategies and Delivery Systems.
    Ling H
    Adv Exp Med Biol; 2016; 937():229-37. PubMed ID: 27573903
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.